Eiger BioPharmaceuticals Profit Margin

Eiger BioPharmaceuticals posts a profit margin of -475.26% as of December 2023. That compares with -717.71% in the prior-year period — up 33.8% year over year. That is below the Healthcare sector average of 14.34%. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Eiger BioPharmaceuticals's profit margin was -717.71%. The latest reading is -475.26% — a 33.8% year-over-year increase (period ending December 2023). Use the history and growth charts on this page for a longer lookback.

For Healthcare stocks, a profit margin near 14.34% is typical. Eiger BioPharmaceuticals's -475.26% is lower that level. That is roughly 3413.1% below the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

Eiger BioPharmaceuticals's profit margin moves when the underlying profit, equity, or asset base changes. Cost cuts, pricing power, buybacks, write-downs, and cyclical swings can all shift the percentage. The latest reading is -475.26% as of December 2023; use YoY and peer views to separate noise from signal.

Context for EIGRQ's profit margin usually means three checks: (1) trend versus prior periods, (2) level versus peers (average 14.34%), and (3) consistency with growth and profitability. This page covers the first two; Eiger BioPharmaceuticals's other metric pages and overview cover the third.